• 1
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJLM. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 205.
  • 2
    McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 42534.
  • 3
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 24465.
  • 4
    IARC. Monographs on the Evaluation of carcinogenic risks to Humans Volume 90: Human Papillomaviruses. Lyon: International Agency for Research on Cancer, 2007.
  • 5
    Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 18316.
  • 6
    Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 15829.
  • 7
    Bulkmans NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 141924.
  • 8
    Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 5137.
  • 9
    Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 12337.
  • 10
    Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 101129.
  • 11
    Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 140612.
  • 12
    Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 141523.
  • 13
    Garcia-Pineres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramirez M, Villegas M, Schiffman M, Rodriguez AC, Burk RD, Hildesheim M, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006; 66: 110706.
  • 14
    Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, Abrahamsen M, Inserra P. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13: 83946.
  • 15
    International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 148195.
  • 16
    International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data on 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 160921.
  • 17
    International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 110824.
  • 18
    Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, van den Brule AJ, Franceschi S, Peeling RW, for the IARC Multi-centric Cervical Cancer Study Group. Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 4319.
  • 19
    Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005; 116: 1105.
  • 20
    Sedjo RL, Papenfuss MR, Craft NE, Giuliano AR. Effect of plasma micronutrients on clearance of oncogenic human papillomavirus (HPV) infection (United States). Cancer Causes Control 2003; 14: 31926.
  • 21
    Piyathilake CJ, Henao OL, Macaluso M, Cornwell PE, Meleth S, Heimburger DC, Partridge EE. Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res 2004; 64: 878893.
  • 22
    Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du Berger R, Ferenczy A, Coutlee F, Franco EL. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 2005; 14: 114956.
  • 23
    Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 7684.
  • 24
    Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008; 123: 168592.
  • 25
    Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 6570.
  • 26
    Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008; 68: 881324.
  • 27
    Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 815.
  • 28
    Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001; 184: 150817.
  • 29
    Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 Suppl 3: S3-78-S3/89.
  • 30
    Arbyn M, Martin-Hirsch P, Buntinx F, Van RM, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009; 13: 64859.
  • 31
    ASCUS and LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 138392.
  • 32
    Massad LS, Jeronimo J, Schiffman M. Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol 2008; 111: 127984.
  • 33
    Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 35761.
  • 34
    Gelman A, Hill J. Analysis using Regression and Multilevel/Hierarchical Models. Cambridge: Cambridge University Press, 2007.
  • 35
    R development core team. R: A Language for Environmental and Statistical Computing. Vienna: R Foundation, 2008.
  • 36
    Plummer M. Improved estimates of floating absolute risk. Stat Med 2004; 23: 93104.
  • 37
    Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003; 12: 47784.
  • 38
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 4238.
  • 39
    Kjaer S, Hogdall E, Frederiksen K, Munk C, Van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006; 66: 106306.
  • 40
    Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer CJLM, Munoz A, for the Instituto Nacional de Cancerologia HPV study group. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 207787.
  • 41
    Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005; 162: 66875.
  • 42
    Molano M, Weiderpass E, Posso H, Morre SA, Ronderos M, Franceschi S, Arslan A, Meijer CJ, Munoz N, van den Brule AJ, and the HPV Study Group. Prevalence and determinants of Chlamydia trachomatis infections in women from Bogota, Colombia. Sex Transm Infect 2003; 79: 4748.
  • 43
    Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 8793.
  • 44
    Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360: 2289.
  • 45
    Molano M, van den Brule AJ, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S, and the HPV Study Group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 48694.
  • 46
    Davey DD, Woodhouse S, Styer P, Stastny J, Mody D. Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 2000; 124: 20311.
  • 47
    Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 9736.